27.9 C
New York
Wednesday, June 10, 2026

Tag: trademark

D3PUBLISHER Announces EARTH DEFENSE FORCE 5 and EARTH DEFENSE FORCE 6 for Nintendo Switch 2

Worldwide launch of EARTH DEFENSE FORCE 5 scheduled for October 8, 2026; EARTH DEFENSE FORCE 6 planned for release this winterTOKYO, June 10, 2026...

Carestream Launches NEW Lux HD 35 and Lux HD 43 Detectors for Medical Imaging

SHANGHAI, June 10, 2026 /PRNewswire/ -- Carestream announces the availability of its new generation of Cesium Iodide (CsI), glass-free X-ray Detector in markets all...

Medmovie Launches HxHeart.com, Bringing Its Trusted Cardiovascular Education Library to Any Browser — and Releases a New Video on the Hidden Risks of Coronary...

The same clinician-approved animations from the Hx Heart app are now available online at HxHeart.com — free, instantly, with no download required.BERKELEY, Calif., June...

UNHCR Recognizes Climate-Resilient Drinking Water Planning Tool as Global Compact on Refugees Good Practice

UNHCR recognizes EPHI’s LSLRCC as a Global Compact on Refugees Good Practice supporting climate-resilient drinking water planning.

Say ‘Bello!’ to the Minions & Monsters Meal, Only at Wendy’s

Wendy's joins Illumination's Minions & Monsters with a custom menu lineup, exclusive collectibles and a drive-thru takeover in Los AngelesFresh Facts:Get ready to experience...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

New Linux Foundation Report Finds AI is Driving Positive Tech Hiring Trends in Europe Amid Growing Security and Skills Gaps

Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...

Australian Retirees Seek Reliable Monthly Income From Global Private Credit as Inflation Bites and TermPlus Targets Up To 8.50%* Per Annum

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

Dow to participate at the 2026 Wells Fargo 16th Annual Industrials & Materials Conference

MIDLAND, Mich., June 5, 2026 /PRNewswire/ -- Dow Inc. (NYSE: DOW) will participate in a fireside chat during the 2026 Wells Fargo 16th Annual Industrials &...

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

Canada’s 2SLGBTQIA+ pioneers commemorated in new stamp issue

2026 Places of Pride stamps honour four more groundbreaking spaces and moments that shaped 2SLGBTQIA+ history ...

- A word from our sponsors -

spot_img
HomeTagsTrademark